Femasys Inc. 8-K Summary
Business Context and Reporting Period
Femasys Inc. (FEMY), an emerging growth company incorporated in Delaware, filed this Current Report on Form 8-K on August 25, 2025. The filing reports the entry into a material definitive agreement regarding an underwritten public offering of equity securities.
Key Financial Metrics and Transaction Details
This filing does not contain historical financial statements, revenue, profit, or cash flow data. The primary financial metric disclosed relates to the proposed capital raise:
- Gross Proceeds: Expected to be $8.0 million before underwriting discounts and offering expenses.
- Securities Offered: 10,434,586 shares of Common Stock, 11,750,000 Pre-Funded Warrants, and 22,184,586 Common Warrants.
- Offering Price: $0.36 per share of Common Stock plus accompanying Common Warrant (except for officer shares at $0.5151).
- Pre-Funded Warrant Price: $0.3599 per warrant with an exercise price of $0.0001.
- Underwriter Warrants: 443,692 warrants issued to underwriters at an exercise price of $0.45.
Material Changes and Transaction Structure
The Company entered into an Underwriting Agreement with JonesTrading Institutional Services LLC and Laidlaw & Company (UK) Ltd. The transaction structure includes:
- Closing Date: Expected on August 27, 2025, subject to customary conditions.
- Use of Proceeds: Expansion of commercial efforts, product development, general corporate purposes, capital expenditures, working capital, and general and administrative expenses.
- Registration: The offering is made pursuant to an effective Form S-1 (Registration No. 333-289722) declared effective on August 25, 2025.
Outlook, Risks, and Management Commentary
Management intends to utilize the net proceeds to fund operational expansion and product development. The filing includes standard forward-looking statements regarding the expected closing and proceeds, noting that actual results may differ due to market conditions and closing conditions. Specific risk factors are referenced in the Company's Form 10-K for the fiscal year ended December 31, 2024. No unusual items or contingencies beyond the standard terms of the underwriting agreement were disclosed.
Investor Verification Checklist
- Verify the final closing of the offering on or around August 27, 2025.
- Confirm the actual net proceeds received after deducting underwriting discounts and commissions.
- Review the final prospectus filed on August 26, 2025, for complete terms of the Pre-Funded Warrants and Common Warrants.
- Monitor subsequent filings for the impact of the new share issuance on existing shareholder dilution.